[1] Miozzo SAS,John JA,Appel-Da-Silva MC, et al. Influence of proton pump inhibitors in the development of spontaneous bacterial peritonitis. J Hepatol,2017,9(35):1278-1285.
[2] Devani K,Charilaou P,Jaiswal P,et al.Trends in hospitalization,acute kidney injury,and mortality in patients with spontaneous bacterial peritonitis. J Clin Gastroenterol,2017,1(14):1329-1334.
[3] 王贵强. 2015年中国慢性乙型肝炎防治指南解读.中国医学前沿杂志(电子版),2016,8(3):1-6.
[4] Mo S,Bendtsen F,Wiese SS,et al.Low ascitic fluid total protein levels is not associated to the development of spontaneous bacterial peritonitis in a cohort of 274 patients with cirrhosis. Scand J Gastroenterol,2018,53(2):200-205.
[5] Fiore M,Maraolo AE,Gentile I,et al.Current concepts and future strategies in the antimicrobial therapy of emerging Gram- positive spontaneous bacterial peritonitis. J Hepatol,2017,9(30):1166-1175.
[6] Cullaro G,Kim G,Pereira MR,et al.Ascites neutrophil gelatinase-associated lipocalin identifies spontaneous bacterial peritonitis and predicts mortality in hospitalized patients with cirrhosis. Digest Dis Sci,2017,62(12):3487-3494.
[7] Fiore M,Maraolo AE,Leone S,et al.Spontaneous peritonitis in critically ill cirrhotic patients:a diagnostic algorithm for clinicians and future perspectives. Ther Clin Risk Manag,2017,13:1409-1414.
[8] Goel A,Rahim U,Nguyen LH,et al.Systematic review with meta-analysis:rifaximin for the prophylaxis of spontaneous bacterial peritonitis. Aliment Pharm Therap,2017,46(11-12):1029-1036.
[9] Garioud A,Cadranel J F,Pauwels A,et al.Albumin use in patients with cirrhosis in France:Results of the “ALBU-LIVE” survey:A case for better EASL guidelines diffusion and/or revision. J Clin Gastroenterol,2017,51(9):831-838.
[10] Sidhu GS,Go A,Attar BM,et al.Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis:a systematic review. Bmj Open,2017,4(1):e000154.
[11] Kamal F,Khan MA,Khan Z,et al.Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis:a systematic review and meta-analysis. Eur J Gastroenterol Hepat,2017,29(10):1109-1117.
[12] Fiore M,Maraolo AE,Gentile I.Nosocomial spontaneous bacterial peritonitis antibiotic treatment in the era of multi-drug resistance pathogens:A systematic review prediction of fungal infection development and their impact on survival using the NACSELD cohort. World J Gastroenterol,2017,23(25):4654-4660.
[13] 占国清,谭华炳,李芳,等. 肝硬化发生自发性细菌性腹膜炎的危险因素分析. 实用肝脏病杂志,2011,14(5):349-350,353.
[14] 徐松波. 双黄连注射液联合哌拉西林治疗肝硬化自发性细菌性腹膜炎疗效观察. 实用肝脏病杂志,2000,5(4):239-240.
[15] Mai M,Stengel S,Alherwi E,et al.Genetic variants of TRAF6 modulate peritoneal immunity and the risk of spontaneous bacterial peritonitis in cirrhosis:A combined prospective-retrosp- ective study. Sci Rep,2017,7(1):4914-4918.
[16] Sideris A,Patel P,Charles HW,et al.Imaging and clinical predictors of spontaneous bacterial peritonitis diagnosed by ultrasound-guided paracentesis. Proceedings,2017,30(3):262-264.
[17] Taneja S,Kumar P,Gautam V,et al.Spontaneous bacterial peritonitis by Burkholderia cepacia complex: A rare,difficult to treat infection in decompensated cirrhotic patients. J Clin Exp Hepatol,2016,7(2):102-106.
[18] Berghe WV,Vermeulen L,Delerive P,et al.A paradigm for gene regulation:Inflammation,NF-κB and PPAR. Adv Exp Med Biol,2003,45(7):544-547.
[19] Ginès P.Management of hepatorenal syndrome in the era of acute-on-chronic liver failure:Terlipressin and beyond. Gastroenterology,2016, 50(7):1525-1528.
[20] Chambel SS,Santosgon alves A,Duarte TL. The dual role of Nrf2 in nonalcoholic fatty liver disease:Regulation of antioxidant defenses and hepatic lipid metabolism. Biomed Res Int,2015,2015(10):2736-2741. |